Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT06040541
Official study title

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Study summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRMC-9805 and RMC-6236

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 3, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?17 U.S. locations

Locations may change over time.

Who runs it?Revolution Medicines, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Revolution Medicines, Inc.
Interventions being studied
Drug: RMC-9805; Drug: RMC-6236
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Biomarkers
KRAS→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
  • Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
  • ECOG performance status 0 or 1
  • Adequate organ function
Reasons someone may not be able to joinExclusion criteria
  • Primary central nervous system (CNS) tumors
  • Known or suspected leptomeningeal or active brain metastases or spinal cord compression
  • Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
  • Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors) Other inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of California, Davis Comprehensive Cancer CenterSacramento, California
  • Smilow Cancer Hospital (Yale University)New Haven, Connecticut
  • Florida Cancer SpecialistsSarasota, Florida
  • Lee Moffitt Cancer CenterTampa, Florida
  • Johns Hopkins UniversityBaltimore, Maryland
  • Massachusetts General HospitalBoston, Massachusetts
  • Dana-Farber Cancer InstituteBoston, Massachusetts
  • NYU LangoneNew York, New York
  • Memorial Sloan Kettering Cancer CenterNew York, New York
  • Duke Cancer CenterDurham, North Carolina
  • Carolina BioOncology InstituteHuntersville, North Carolina
  • The Christ HospitalCincinnati, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 3, 2026. Always confirm current availability with the study team.

View original record ↗